Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019043382 - LEPTIN PEPTIDES AND THEIR USE FOR TREATING NEUROLOGICAL DISORDERS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

What is claimed is:

1. A leptin peptide fragment comprising at least 4 consecutive amino acids located within the region of amino acids 116 - 125 of leptin for use in a method of treating a

neurological disorder,

2. A method of treating a neurological disorder comprising administering to a subject in need a leptin peptide fragment comprising at least 4 consecutive amino acids located within the region of amino acids 116 - 125 of leptin.

3. The leptide peptide fragment for use in a method according to claim 1, or the method according to claim 2 wherein the leptin peptide fragment comprises up to 30 amino acids.

4. The leptide peptide fragment for use in a method, or the method according to any

preceding claim , wherein the leptin peptide fragment comprises one or more amino acids located between amino acids 116 - 122 of leptin.

5. The leptide peptide fragment for use in a method, or the method according to any

preceding claim comprising the sequence:

X1CX2LPX3X4

wherein XI is selected from G or S; X2 is selected from S, H or P; X3 is selected from Q, H, W, L, P or R and X4 is selected from T, A, or V (SEQ ID NO: 14).

6. The leptide peptide fragment for use in a method, or the method according to any

preceding comprising amino acids selected from the group consisting of 116 -121 of leptin, 117 - 122 of leptin, 117 - 125 of leptin, 118 - 123 of leptin, 119 - 124 of leptin, 120 - 125 of leptin, and 116 - 130 of leptin.

7. The leptide peptide fragment for use in a method, or the method according to any

preceding claim wherein the leptin sequence is derived from human leptin.

8. The leptide peptide fragment for use in a method, or the method according to any

preceding claim, wherein the 116 - 125 region of leptin has the sequence

SCHLPWASGL (SEQ ID NO:22).

9. The leptide peptide fragment for use in a method, or the method according to any

preceding claim comprising 1, 2, or 3 deletions, modifications, substitutions and/or additions to the amino acid sequence.

10. The leptide peptide fragment for use in a method, or the method according to any preceding claim, wherein the leptin peptide fragment is in the form of a cyclic peptide.

11. The leptide peptide fragment for use in a method, or the method according to any preceding claim wherein the peptide is in the form of a peptide conjugate, wherein the leptin peptide fragment is conjugated to another peptide, or non-peptide molecule.

12. The leptide peptide fragment for use in a method, or the method according to any preceding claim wherein the other peptide or non-peptide molecule is a biologically or pharmaceutically active agent.

13. The leptide peptide fragment for use in a method, or the method according to any preceding claim wherein the neurological disorder is a disorder which would benefit from treatment through cognitive enhancement and/or neuroprotection.

14. The leptide peptide fragment for use in a method, or the method according to any preceding claim wherein the neurological disorder is selected from the group consisting of age-associated memory impairment or loss, mild cognitive impairment, and Alzheimer's disease.

15. The leptide peptide fragment for use in a method, or the method according to any preceding claim wherein the neurological disorder is selected from the group consisting of Parkinson's disease, frontotemporal dementia, progressive supranuclear palsy, Pick's disease, corticobasal degeneration, alcoholic dementia, (DLB) dementia with Lewy bodies, Picks' disease, thalamic dementia, hippocampal sclerosis,

Hallervorden-Spatz, multiple system atrophy, tauopathies, subacute aterioscleroitic encephalopathy (Binswanger's disease), amyloid angiopathy, vasculitis, prion diseases, and paraneoplastic syndromes.

16. A pharmaceutical formulation comprising a leptin peptide fragment comprising at least 4 consecutive amino acids located within the region of amino acids 116 - 125 of leptin.

17. The pharmaceutical formulation according to claim 15 wherein the leptin peptide fragment comprises up to 30 amino acids.

18. The pharmaceutical formulation according to claim 15 or 16 wherein the leptin

peptide fragment comprises one or more amino acids located between amino acids 116 - 122 of leptin.

19. The pharmaceutical formulation according to any of claims 15 - 17 comprising the sequence:

X1CX2LPX3X4

wherein XI is selected from G or S; X2 is selected from S, H or P; X3 is selected from Q, H, W, L, P or R and X4 is selected from T, A, or V (SEQ ID NO: 14).

20. The pharmaceutical formulation according to any of claims claim 15 - 18 wherein the leptin peptide fragment comprises amino acids selected from the group consisting of

116 -121 of leptin, 117 - 122 of leptin, 117 - 125 of leptin, 118 - 123 of leptin, 119 - 124 of leptin, 120 - 125 of leptin, and 116 - 130 of leptin.

21. The pharmaceutical formulation according to any of claims 15 - 19, wherein the leptin peptide sequence is derived from human leptin.

22. The pharmaceutical formulation according to any of claims 15 - 20 wherein the 116—

125 region of leptin has the sequence SCHLPWASGL (SEQ ID NO:22).

23. The pharmaceutical formulation according to any of claims 15 - 21 comprising 1, 2, or 3 deletions, modifications, substitutions and/or additions to the amino acid sequence.

24. The pharmaceutical formulation according to any of claims 15 - 22 wherein the leptin peptide fragment is in the form of a cyclic peptide.

25. The pharmaceutical formulation according to any of claims 15 - 23 wherein the

peptide is in the form of a peptide conjugate, wherein the leptin peptide fragment is conjugated to another peptide, or non-peptide molecule.

26. The pharmaceutical formulation according to any of claims 15 - 24 wherein the other peptide or non-peptide molecule is a biologically or pharmaceutically active agent.

27. A cyclic peptide or peptide conjugate comprising a leptin peptide fragment comprising at least 4 consecutive amino acids located within the region of amino acids 116 - 125 of leptin.

28. The cyclic peptide or peptide conjugate according to claim 26 wherein the leptin peptide fragment comprises up to 30 amino acids.

29. The cyclic peptide or peptide conjugate according to claims 26 or 27 wherein the leptin peptide fragment comprises one or more amino acids located between amino acids 116 - 122 of leptin.

30. The cyclic peptide or peptide conjugate according to any of claims 26 - 28 comprising the sequence:

X1CX2LPX3X4

wherein XI is selected from G or S; X2 is selected from S, H or P; X3 is selected from Q, H, W, L, P or R and X4 is selected from T, A, or V (SEQ ID NO: 14).

31. The cyclic peptide or peptide conjugate according to any of claims 26 - 29 wherein the leptin peptide fragment comprises amino acids selected from the group consisting of 116 -121 of leptin, 117 - 122 of leptin, 117 - 125 of leptin, 118 - 123 of leptin,

119 - 124 of leptin, 120 - 125 of leptin, and 116 - 130 of leptin.

32. The cyclic peptide or peptide conjugate according to any of claims 26 - 30, wherein the leptin peptide sequence is derived from human leptin.

33. The cyclic peptide or peptide conjugate according to any of claims 26 - 31 wherein the 116 - 125 region of leptin has the sequence SCHLPWASGL (SEQ ID NO:22).

34. The cyclic peptide or peptide conjugate according to any of claims 26 - 32 comprising

1, 2, or 3 deletions, modifications, substitutions and/or additions to the amino acid sequence.